Point-of-care testing for common sexually transmitted infections may reduce overuse of antibiotics and improve emergency ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

Point-of-care PCR testing for STIs in the ED reduced length of stay and improved antibiotic stewardship compared with central laboratory testing.

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

Explore MyBioSource's premium PCR kits for disease detection and genetic research, offering fast, accurate results for oncology, infectious diseases, and more.

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...

IVDs are essential for disease detection, personalized treatment, and public health, driving growth in the global diagnostics ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

The "Veterinary Infectious Disease Diagnostics Market - A Global and Regional Analysis: Focus on Technology, Product, Animal Type, Infection Type, End user, Country, and Region - Analysis and Forecast ...

In a significant development in the fight against COVID-19, the World Health Organization (WHO) has prequalified two rapid antigen tests for detecting the virus. This landmark decision, announced last ...

The Australian patent represents the first patent granted for the Company's new point-of-care testing platform ...